- Home
- OCFC vs PHAR Comparison
OCFC vs PHAR Comparison
Compare OCFC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCFC
- PHAR
- Stock Information
- Founded
- OCFC 1902
- PHAR 1988
- Country
- OCFC United States
- PHAR Netherlands
- Employees
- OCFC N/A
- PHAR N/A
- Industry
- OCFC Major Banks
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- OCFC Finance
- PHAR Health Care
- Exchange
- OCFC Nasdaq
- PHAR Nasdaq
- Market Cap
- OCFC 1.1B
- PHAR 951.7M
- IPO Year
- OCFC 1996
- PHAR N/A
- Fundamental
- Price
- OCFC $18.91
- PHAR $13.48
- Analyst Decision
- OCFC Buy
- PHAR Strong Buy
- Analyst Count
- OCFC 4
- PHAR 3
- Target Price
- OCFC $21.75
- PHAR $30.00
- AVG Volume (30 Days)
- OCFC 459.1K
- PHAR 10.7K
- Earning Date
- OCFC 10-22-2025
- PHAR 11-06-2025
- Dividend Yield
- OCFC 4.28%
- PHAR N/A
- EPS Growth
- OCFC N/A
- PHAR N/A
- EPS
- OCFC 1.30
- PHAR N/A
- Revenue
- OCFC $378,558,000.00
- PHAR $339,836,000.00
- Revenue This Year
- OCFC N/A
- PHAR $17.70
- Revenue Next Year
- OCFC $11.03
- PHAR $12.25
- P/E Ratio
- OCFC $14.39
- PHAR N/A
- Revenue Growth
- OCFC N/A
- PHAR 22.44
- 52 Week Low
- OCFC $14.29
- PHAR $7.31
- 52 Week High
- OCFC $21.87
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- OCFC 56.50
- PHAR 44.81
- Support Level
- OCFC $17.90
- PHAR $13.08
- Resistance Level
- OCFC $19.50
- PHAR $14.81
- Average True Range (ATR)
- OCFC 0.79
- PHAR 0.48
- MACD
- OCFC 0.08
- PHAR -0.14
- Stochastic Oscillator
- OCFC 72.81
- PHAR 23.12
About OCFC OceanFirst Financial Corp.
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.